SEC Form 4 · accession 0001203311-17-000084
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan G Drachman
Officer — CMO & EVP, R & D
Period of report
Oct 5, 2017
Accepted (ET)
Oct 10, 2017 · 6:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 5, 2017 | M | 7,249 | $11.09 | A | 140,951 | D | |
| Common StockF1 | Oct 5, 2017 | M | 2,344 | $10.61 | A | 143,295 | D | |
| Common StockF1 | Oct 5, 2017 | M | 8,223 | $12.16 | A | 151,518 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F2 | $10.61 | Oct 5, 2017 | M | 2,344 | D | — | May 7, 2020 | Common Stock | 2,344 | 0 | D |
| Incentive Stock Option (right to buy)F3 | $11.09 | Oct 5, 2017 | M | 7,249 | D | — | Aug 27, 2018 | Common Stock | 7,249 | 0 | D |
| Incentive Stock Option (right to buy)F4 | $12.16 | Oct 5, 2017 | M | 8,223 | D | — | Aug 25, 2019 | Common Stock | 8,223 | 0 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2Shares vested at a rate of 25% on 5/7/11 and monthly thereafter until all the shares were fully vested on 5/7/14.
- F3Shares vested at a rate of 25% on 8/27/09 and monthly thereafter until all the shares were fully vested on 8/27/12.
- F4Shares vested at a rate of 25% on 8/25/10 and monthly thereafter until all the shares were fully vested on 8/25/13.